Resolutions at Aerocrine's Extraordinary General Meeting

Resolutions at Aerocrine's Extraordinary General Meeting

An Extraordinary General Meeting (EGM) was held in Aerocrine AB (NASDAQ
OMX Stockholm: AERO) on 16 November 2011 in Stockholm. The EGM resolved
to approve the proposal by the Board of Directors on the implementation
of a long-term incentive program (LIP 2011) and the issuance and
approval of transfer of warrants. Thomas Eklund was elected new member
of the Board.

LIP 2011 is, among other things, part of Aerocrine's strategy to build
and strengthen the company's U.S. operations and commercial
organization. In brief, under LIP 2011 a total of not more than
10,000,000 employee stock options (ESOs) will be allotted free of charge
to approximately 80 current and, in addition thereto, future senior
executives and other employees within the group as well as other key
persons, including scientific and clinical consultants. The ESOs will
entitle to the acquisition of shares in Aerocrine. In order to enable
the delivery of shares and otherwise safeguard the fulfillment of
Aerocrine's obligations under LIP 2011, the EGM resolved on the issuance
of not more than 8,648,461 warrants to the wholly-owned subsidiary
Aerocrine ESOP AB and approved that the warrants, as well as part of the
warrants issued in conjunction with the implementation of Aerocrine's
2007 and 2009 incentive programs, may be transferred and disposed of
under LIP 2011.

The meeting also resolved to elect Thomas Eklund new member of the
Board. As previously announced, Karl Swartling stepped down from the
Board in conjunction with the EGM.

For complete information regarding the resolutions by the EGM, please
visit www.aerocrine.se where documentation related to the EGM is
available for download.

For more information, contact:

Anders Williamsson, Chairman of the Board, telephone +46 708 721 865.